SAR444559
/ Sanofi
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
February 02, 2024
A first-in-human study to investigate subcutaneous doses of SAR444559 compared with placebo in healthy adult participants.
(ANZCTR)
- P1 | N=102 | Terminated | Sponsor: Sanofi-Aventis Australia Pty Ltd | Active, not recruiting ➔ Terminated
Trial termination • Immunology
November 11, 2023
A first-in-human study to investigate subcutaneous doses of SAR444559 compared with placebo in healthy adult participants.
(ANZCTR)
- P1 | N=102 | Active, not recruiting | Sponsor: Sanofi-Aventis Australia Pty Ltd | Recruiting ➔ Active, not recruiting
Enrollment closed • Immunology
September 01, 2023
A first-in-human study to investigate subcutaneous doses of SAR444559 compared with placebo in healthy adult participants.
(ANZCTR)
- P1 | N=102 | Recruiting | Sponsor: Sanofi-Aventis Australia Pty Ltd | Initiation date: Dec 2000 ➔ Dec 2022
Trial initiation date • Immunology
1 to 3
Of
3
Go to page
1